Hedgepath Pharmaceuticals Inc (HPPI) financial statements (2021 and earlier)

Company profile

Business Address 4830 W. KENNEDY BLVD.
TAMPA, FL 33609
State of Incorp. DE
Fiscal Year End December 31
SIC 8731 - Commercial Physical and Biological Research (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments0110710
Cash and cash equivalents0110710
Prepaid expense0000000
Deposits current assets   00  
Total current assets:0111710
Noncurrent Assets
Other noncurrent assets000000 
Total noncurrent assets:000000 
TOTAL ASSETS:0111710
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities0001000
Accounts payable0001000
Accrued liabilities      0
Interest and dividends payable000    
Debt0      
Other liabilities0000000
Other undisclosed current liabilities      (0)
Total current liabilities:0011000
Noncurrent Liabilities
Long-term debt and lease obligation0      
Long-term debt, excluding current maturities0      
Liabilities, other than long-term debt33     
Deferred revenue33
Other undisclosed noncurrent liabilities0 1    
Total noncurrent liabilities:331    
Total liabilities:3311000
Stockholders' equity
Stockholders' equity attributable to parent, including:(3)(3)00700
Common stock0000000
Additional paid in capital50494948503732
Accumulated deficit(57)(56)(53)(48)(43)(36)(32)
Other undisclosed stockholders' equity attributable to parent444    
Total stockholders' equity:(3)(3)00700
TOTAL LIABILITIES AND EQUITY:0111710

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Operating expenses(1)(3)(5)(5)(7)(4)(4)
Operating loss:(1)(3)(5)(5)(7)(4)(4)
Interest and debt expense      (0)
Loss before gain (loss) on sale of properties:(1)(3)(5)(5)(7)(4)(4)
Other undisclosed net income000    
Net loss:(1)(3)(5)(5)(7)(4)(4)
Other undisclosed net income attributable to parent   00  
Net loss available to common stockholders, diluted:(1)(3)(5)(5)(7)(4)(4)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(1)(3)(5)(5)(7)(4)(4)
Comprehensive loss, net of tax, attributable to parent:(1)(3)(5)(5)(7)(4)(4)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: